Skip to main
DRTS

DRTS Stock Forecast & Price Target

DRTS Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Tau Medical is currently in a favorable position with its strategic U.S. partnership with Tolmar, a strong runway of cash through 2027, and upcoming data from its U.S. pancreatic cancer pilot study and ongoing clinical trials. The company's Alpha DaRT technology shows promising results and has the potential to be a compelling localized radiation therapy for several types of solid tumors. However, risks such as failure in clinical trials, regulatory approval, and achieving commercial success should be closely monitored. Overall, Alpha Tau Medical has a strong potential for growth and is a Buy with a 12-month price target of $15 per share.

Bears say

Alpha Tau Medical is a clinical-stage oncology therapeutics company, but with a lack of commercial success potential due to market size, penetration rate, and competition, as well as a potential dilution risk. Additionally, the failure of Alpha DaRT to secure regulatory approval in the U.S. and potential failure in clinical trials are major risks. Return on Investment (ROI) and revenue generation are also uncertain, making Alpha Tau Medical's stock a high-risk investment with a negative outlook.

DRTS has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Tau Medical (DRTS) Forecast

Analysts have given DRTS a Buy based on their latest research and market trends.

According to 5 analysts, DRTS has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Tau Medical (DRTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.